These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7997419)

  • 1. Response to prostaglandin E1 in neonates with intracranial arteriovenous malformation treated for suspected congenital heart disease.
    Covert RF
    Pediatr Cardiol; 1994; 15(2):81-4. PubMed ID: 7997419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E1 in infants with congenital heart disease: Indian experience.
    Saxena A; Sharma M; Kothari SS; Juneja R; Reddy SC; Sharma R; Bhan A; Venugopal P
    Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nursing care of the neonate receiving prostaglandin E1 therapy.
    Rikard DH
    Neonatal Netw; 1993 Jun; 12(4):17-22. PubMed ID: 8510622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects.
    Tálosi G; Katona M; Rácz K; Kertész E; Onozó B; Túri S
    J Perinat Med; 2004; 32(4):368-74. PubMed ID: 15346826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 treatment of congenital heart disease: use prior to neonatal transport.
    Buck ML
    DICP; 1991 Apr; 25(4):408-9. PubMed ID: 1926911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supportive and emergency use of prostaglandin in the neonate with congenital heart disease.
    Hussain A; al Khudhairi D
    Middle East J Anaesthesiol; 1993 Feb; 12(1):73-81. PubMed ID: 8316154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.
    Ohara T; Ogata H; Fujiyama J; Murata Y; Abe J; Kakuta K; Hayamizu S; Kameyama S; Yoshida Y
    Tohoku J Exp Med; 1985 Jun; 146(2):237-49. PubMed ID: 4040664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.
    Reddy SC; Saxena A
    Indian J Pediatr; 1998; 65(2):211-6. PubMed ID: 10771966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease.
    Stone DM; Frattarelli DA; Karthikeyan S; Johnson YR; Chintala K
    Pediatr Cardiol; 2006; 27(3):360-3. PubMed ID: 16565906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infusion of prostaglandin E1 in ductus-dependent congenital heart diseases. Analysis of 47 cases].
    Atik E; Gutiérrez JA; Lyra Filho FJ; Iwahashi ER; Ribeiro IG; De Albuquerque AM; Barbero-Marcial M; Ebaid M
    Arq Bras Cardiol; 1989 Aug; 53(2):93-7. PubMed ID: 2624556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of prostaglandin E1 in neonates with critical congenital cardiac defects.
    Lewis AB; Takahashi M; Lurie PR
    J Pediatr; 1978 Sep; 93(3):481-5. PubMed ID: 690772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic dilatation of the ductus arteriosus with prostaglandin E1 in infants with congenital heart disease.
    Graham TP; Atwood GF; Boucek RJ
    South Med J; 1978 Oct; 71(10):1238-41, 1246. PubMed ID: 81528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transporting newborn infants with suspected duct dependent congenital heart disease on low-dose prostaglandin E1 without routine mechanical ventilation.
    Browning Carmo KA; Barr P; West M; Hopper NW; White JP; Badawi N
    Arch Dis Child Fetal Neonatal Ed; 2007 Mar; 92(2):F117-9. PubMed ID: 16905574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of preoperative administration of prostaglandin E1 on cerebral blood flow in newborns with ductal-dependent congenital cardiac malformations].
    Simon M; Cucerea M; Dimitriu AG; Stamatin M
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):399-407. PubMed ID: 20700975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.
    Leonhardt A; Schweer H; Wolf D; Seyberth HW
    Br J Clin Pharmacol; 1992 Mar; 33(3):323-5. PubMed ID: 1576056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostaglandin E1 in newborn infants with ductus-dependent heart diseases. Review of 40 cases].
    Simões LC; Sarachaga IH; Quero M; Casanova M; Cazzaniga M; Villibre D
    Arq Bras Cardiol; 1985 Jul; 45(1):31-6. PubMed ID: 3938651
    [No Abstract]   [Full Text] [Related]  

  • 18. Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant.
    Strauss A; Modanlou HD; Gyepes M; Wittner R
    Am J Dis Child; 1982 Oct; 136(10):934-6. PubMed ID: 6889810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostaglandin E1 therapy in infants with cyanotic congenital heart malformations: hemodynamic and angiographic findings (author's transl)].
    Schumacher G; Mocellin R; Schöber JG; Kellner M; Bühlmeyer K
    Klin Padiatr; 1978 Sep; 190(5):465-73. PubMed ID: 568198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined prostaglandin therapy and ductal formalin infiltration in neonatal pulmonary oligemia.
    Larson JE; Fleming WH; Sarafian LB; Rogler WC; Hofschire PJ; McManus BM
    J Thorac Cardiovasc Surg; 1985 Dec; 90(6):907-11. PubMed ID: 4068741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.